Patent ID: 9623096
Date: 2017-04-18
CPC Classifications: A61K,C12N

Claim:
1. A method of preparing an immunogenic formulation for treating a patient, the method comprising: obtaining uninfected hematopoietic cancer cells from the patient; testing and quantifying the uninfected hematopoietic cancer cells from the patient for expression of CD40 on cells; infecting, ex-vivo, the obtained uninfected hematopoietic cancer cells with an oncolytic rhabdovirus that modulates the expression of endogenous immune regulatory molecules including CD40 to increase the immunogenicity of the infected hematopoietic cancer cells; incubating the infected hematopoietic cancer cells to generate infected hematopoietic cancer cells having increased immunogenicity; testing and quantifying the infected hematopoietic cancer cells in the formulation for expression of CD40 on cells; and formulating the rhabdovirus-infected hematopoietic cancer cells having increased immunogenicity into a formulation wherein, the concentration of infected hematopoietic cancer cells expressing CD40 is greater than the concentration of uninfected hematopoietic cancer cells expressing CD40.